## Topical immunotherapeutic agent for atopic dermatitis: FPR2-selective pro-resolving peptide ligand

## Novacell Technology Inc.



Product Type	IMMUNOLOGY	Phase 1
patients: Mild-to-Moderate)  Secondary indication: Psoriasis, Dry eye syndrome (eye drop) [MeSH term] (Target patients: Mild-to-Severe)  Target  Formyl peptide Receptor 2 (FPR2)  MOA(Mechanism of Action)  NCP112 is a FPR2-specific peptide ligand acting as a pro-resolving factor through FPR2 activation  Resolution  FPP TROID  FPP	Product Type	Peptide Product (7-mer, N-terminal lipidation)
NCP112 is a FPR2-specific peptide ligand acting as a pro-resolving factor through FPR2 activation    NCP112 is a FPR2-specific peptide ligand acting as a pro-resolving factor through FPR2 activation   PR2 activation	Indication	patients: Mild-to-Moderate) • Secondary indication: Psoriasis, Dry eye syndrome (eye drop) [MeSH term] (Target
Processory of the point of the process of the point of th	Target	Formyl peptide Receptor 2 (FPR2)
Pro-resolution   Pro-re	MoA(Mechanism of Action)	
Differential Point  • First-in-class immunotherapeutic agent targeting FPR2, a validated molecular target to induce resolution of inflammation • Efficacy on characteristic symptoms of atopic dermatitis including skin inflammation, skin barrier disruption, and pruritus • Safety profile confirmed in Preclinical/Clinical study to meet unmet medical needs for long-term treatment as a topical agent • Convenient administration route for mild-to-moderate patients along with lower cost of treatment compared to biologics  Phase 1 (Application for Phase II clinical trial is scheduled on 1st quarter of 2023)		Onset  Anti- inflammatory Diseases  New of infection A Imapproportate adaptive response  Pro-resolution  Risk of infection P Pro-resolution  Risk of infection P Proper adaptive response  Pro-resolution  Risk of infection P Proper adaptive response  Peptition  Perturbation  Per
Differential Point  • First-in-class immunotherapeutic agent targeting FPR2, a validated molecular target to induce resolution of inflammation • Efficacy on characteristic symptoms of atopic dermatitis including skin inflammation, skin barrier disruption, and pruritus • Safety profile confirmed in Preclinical/Clinical study to meet unmet medical needs for long-term treatment as a topical agent • Convenient administration route for mild-to-moderate patients along with lower cost of treatment compared to biologics  Development Stage  Phase 1 (Application for Phase II clinical trial is scheduled on 1st quarter of 2023)		CRCRs [Figure 1.12]
molecular target to induce resolution of inflammation  • Efficacy on characteristic symptoms of atopic dermatitis including skin inflammation, skin barrier disruption, and pruritus  • Safety profile confirmed in Preclinical/Clinical study to meet unmet medical needs for long-term treatment as a topical agent  • Convenient administration route for mild-to-moderate patients along with lower cost of treatment compared to biologics  Development Stage  Phase 1 (Application for Phase II clinical trial is scheduled on 1st quarter of 2023)		GPR38
2023)	Differential Point	<ul> <li>molecular target to induce resolution of inflammation</li> <li>Efficacy on characteristic symptoms of atopic dermatitis including skin inflammation, skin barrier disruption, and pruritus</li> <li>Safety profile confirmed in Preclinical/Clinical study to meet unmet medical needs for long-term treatment as a topical agent</li> <li>Convenient administration route for mild-to-moderate patients along with</li> </ul>
Route of Administration Topical (Dermal)	Development Stage	
	Route of Administration	Topical (Dermal)

